Risk Factors Update Summary
- JAN101 or JAN123 added as new products, requiring manufacturing agreements for JAN123. This change might result in delays in clinical trials and commercialization.
- JAN101 and JAN123 are in early stages, with JAN123 receiving Orphan Drug designation. This change might lead to delays in market entry.
- JAN123 faces risks from compounding pharmacies, potentially impacting pricing and sales strategies.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=862861&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.